AlphAIAlphAI — Financial news for AI agents
equitypandit.comOCT 191 min read

Divi’s Labs Gains 2% as Eli Lilly Pill Wins EU Panel Nod

Divi’s Laboratories shares rose 2% after an EU panel recommended approval for Eli Lilly’s weight-loss pill, Foundayo. The company, which manufactures pharmaceutical ingredients, reported a 65.5% increase in Q2 net profit to Rs 902 crore. Divi’s has not announced any role in the drug. The stock traded at Rs 9,241.00 on NSE.

Original reporting
equitypandit.com
Published Oct 19, 2026, 6:06 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 19, 2026, 7:35 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Divi’s Labs Gains 2% as Eli Lilly Pill Wins EU Panel Nod — source image
Source · equitypandit.com
Decision brief

The 30-second read

Med
01

Why it matters

The EMA opinion provides a near‑term boost to sentiment for pharma contract manufacturers, but the ultimate impact depends on final approval and market uptake of the drug.

02

Market read

Divi's stock movement reflects broader market interest in obesity‑drug pipelines, offering a short‑term trading angle.

03

What to watch

Divi's own pipeline and earnings growth remain the primary drivers of its valuation, independent of the Lilly pill news.

Relevance 7/10Novelty 7/10Timing: pre-market today

Background

Divi's Laboratories is an Indian API manufacturer that supplies active ingredients to global drug makers. The article links its stock rise to a positive EMA opinion on Eli Lilly's weight‑loss drug.

Market effects

Sector

Weight‑loss pharma sector gains attention as EMA opinion on Eli Lilly's pill may boost demand for contract manufacturers.

Regional

Indian pharma stocks see modest uplift, with Divi's Laboratories leading the move.

Global

European regulatory outlook for obesity drugs could influence global pharma supply chains.

Counterpoint

What could challenge this read

The EMA opinion is non‑binding; without final approval the catalyst may fade, limiting upside for contract manufacturers.

Key entities

  • company
    Divi's Laboratories Ltd

    Indian API manufacturer whose shares rose 2% on the news.

  • company
    Eli Lilly and Co.

    Developer of the weight‑loss pill receiving EMA positive opinion.

Read at source← All news

Related articles

OCT 19
$LLYMed

Your Questions Answered: Foundayo’s EU Panel Backing, Enspryng for TED, Gilead’s Masked TCE Bet, FDA’s Rare Disease Overhaul, and More

Eli Lilly's Foundayo received a positive CHMP opinion for EU marketing authorization for weight management and type 2 diabetes. Roche's Enspryng gained FDA approval for thyroid eye disease. AstraZeneca partnered with insitro for AI-driven drug discovery in MASH and cardiomyopathies. The FDA launched a Rare Disease Framework Initiative to improve drug development for rare diseases. Gilead and Vir Biotechnology agreed to a $1.87 billion collaboration for masked T-cell engagers.

pharmexec.com3 min
OCT 19
$LLYHigh

Eli Lilly (LLY) Reports Positive Phase 3 SHINE-2 Trial Results f

Eli Lilly (LLY) reported positive Phase 3 SHINE-2 trial results for Omvoh in pediatric ulcerative colitis, showing 81% clinical response and 50% remission rates. The company's GF Value™ suggests a 20.4% undervaluation, with a GF Score™ of 96/100. Insider selling totaled $2.66 billion over 12 months, while 25 gurus hold the stock with balanced activity. LLY's P/E ratio is 42.71x, below its 5-year median of 53.19x.

gurufocus.com2 min
OCT 19
$LLYMed

Lilly reports positive pediatric ulcerative colitis trial data

Eli Lilly (NYSE:LLY) reported that its drug Omvoh met the primary endpoint in a Phase 3 study for pediatric ulcerative colitis. The SHINE-2 study showed 81% of patients achieved clinical response at Week 12, with 50% of responders in clinical remission at Week 52. The company plans to submit the data to global regulators for potential label expansion. Omvoh is already approved for adults in 47 countries.

investing.com2 min
OCT 19
$LLYHigh

Lilly's Omvoh (mirikizumab-mrkz) meets primary endpoint of clinical remission and is the first IL-23p19 inhibitor to report one-year Phase 3 results in pediatric ulcerative colitis

Eli Lilly's Omvoh (mirikizumab-mrkz) met the primary endpoint of clinical remission in a Phase 3 study for pediatric ulcerative colitis, with 50% of responders achieving remission at one year. The company plans to submit these data to regulators for potential label expansion. Omvoh is currently approved for adults with the condition.

prnewswire.com2 min